TG Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by TG Therapeutics, Inc. on June 18, 2018. The report discloses the entry into a Material Definitive Agreement with Novimmune SA regarding the development and commercialization of a novel therapeutic asset.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The primary financial disclosure relates to the terms of the new agreement:
- Upfront Payment: $3 million in shares of the Company's common stock.
- Development Costs: TG Therapeutics is responsible for costs through the end of Phase 2 clinical trials; thereafter, costs are shared jointly with Novimmune.
- Potential Future Payments: Approximately $185 million in additional payments and tiered royalties (high single to low double digits) contingent on the exercise of an exclusive license option.
Material Changes
The material change reported is the execution of a Joint Venture and License Option Agreement with Novimmune SA. The agreement focuses on TG-1801 (previously NI-1701), a first-in-class anti-CD47/anti-CD19 bispecific antibody targeting hematologic B-cell malignancies. TG Therapeutics serves as the primary responsible party for development, manufacturing, and commercialization.
Outlook, Risks, and Contingencies
Management commentary indicates a strategic collaboration to advance TG-1801 on a worldwide basis. Key contingencies include:
- License Option: Both parties maintain an exclusive option for TG Therapeutics to license the rights to TG-1801 at specific times during development.
- Regulatory Filing: The Company agreed to file a resale registration statement for the $3 million stock payment.
- Cost Sharing: Financial responsibility shifts from TG Therapeutics solely to a joint arrangement after Phase 2 trials.
Investor Verification Checklist
- Verify the terms of the resale registration statement for the $3 million stock issuance.
- Review the full text of the Joint Venture and License Option Agreement (to be filed as an exhibit to the next periodic report) for specific milestone triggers.
- Confirm the timeline for the Phase 2 clinical trials to understand the duration of TG Therapeutics' sole cost responsibility.
- Assess the impact of the $3 million stock issuance on existing shareholder dilution.